Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0,47%
1 067,36
+4,96
+0,47%
—1 062,401 064,141 071,991 061,02——
SIXC
Communications
SIXC
Communications
SIXC
-0,54%
603,48
-3,26
-0,54%
—606,74606,74609,84602,33——
SIXE
Energy
SIXE
Energy
SIXE
+0,54%
1 244,93
+6,72
+0,54%
—1 238,211 236,601 247,741 232,10——
SIXI
Industrials
SIXI
Industrials
SIXI
+0,68%
1 730,38
+11,77
+0,68%
—1 718,611 723,231 741,481 717,47——
SIXM
Financials
SIXM
Financials
SIXM
+0,33%
639,47
+2,10
+0,33%
—637,37638,27642,30638,27——
SIXR
Staples
SIXR
Staples
SIXR
+0,16%
854,95
+1,36
+0,16%
—853,59854,05858,19851,34——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0,11%
218,56
+0,23
+0,11%
—218,33218,33219,73217,15——
SIXT
Technology
SIXT
Technology
SIXT
+1,02%
3 631,59
+36,78
+1,02%
—3 594,813 620,103 657,473 615,34——
SIXU
Utilities
SIXU
Utilities
SIXU
+0,80%
915,77
+7,23
+0,80%
—908,54909,50917,35907,07——
SIXV
Health care
SIXV
Health care
SIXV
+1,19%
1 512,81
+17,81
+1,19%
—1 495,001 499,611 517,101 499,61——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,41%
2 408,21
+9,90
+0,41%
—2 398,312 406,822 421,802 404,22——
RPGLIFE:NSE
RPG Life Sciences Ltd
₹2 298,30
+1,06%
(+24,10) 1D
22 Mei, 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for RPGLIFE...
Open
₹2 274,20
High
₹2 329,00
Low
₹2 253,60
Mkt. cap
37,94 mjd
Avg. vol.
78,74 k
Volume
5,92 k
P/E ratio
33,00
52-wk high
₹2 725,00
52-wk low
₹1 733,00
EPS
₹69,64
Shares outstanding
16,54 m
No. of employees
1 k
News stories
From sources across the web
Profile
RPG Life Sciences is an Indian pharmaceutical company. Formerly known as Searle Ltd, RPG Life Sciences is part of RPG Enterprises. It has its corporate office in RPG House in Worli, Mumbai. Its three major activities are the manufacturing and marketing of bulk drugs, also known as active pharmaceutical ingredients; pharmaceutical formulation; and fermentation and biotechnology. RPGLS is present in the domestic as well as the international market. It exports its products primarily to Europe, Latin America, Australia and South East Asian countries. Wikipedia
About RPG Life Sciences Ltd
CEO-
Employees1,33 k
Founded1993
Headquarters-
SectorPharmaceutical industry
Websiterpglifesciences.com
Last report
30 Apr. 2026
Fiscal period
Q4 2026
EPS / Est. (INR)
- / -
Revenue / Est. (INR)
1,77 mjd / -
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Jun. 2025
Sep. 2025
Des. 2025
Mrt. 2026
Revenue
1,69 mjd
1,82 mjd
1,80 mjd
1,77 mjd
Cost of goods sold
600,20 m
665,80 m
649,00 m
605,90 m
Cost of revenue
600,20 m
665,80 m
649,00 m
605,90 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
337,00 m
361,60 m
353,20 m
363,00 m
Operating expense
785,70 m
812,90 m
807,50 m
892,10 m
Total operating expenses
1,39 mjd
1,48 mjd
1,46 mjd
1,50 mjd
Operating income
303,30 m
338,10 m
343,80 m
270,90 m
Other non operating income
52,30 m
45,40 m
34,10 m
44,90 m
EBT including unusual items
354,30 m
494,50 m
291,20 m
402,00 m
EBT excluding unusual items
354,30 m
382,30 m
375,40 m
311,90 m
Income tax expense
91,40 m
126,00 m
69,90 m
103,00 m
Effective tax rate
25,80%
25,48%
24,00%
25,62%
Other operating expenses
397,30 m
399,10 m
400,50 m
471,70 m
Net income
262,90 m
368,50 m
221,30 m
299,00 m
Net profit margin
15,56%
20,28%
12,29%
16,90%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-1,30 m
-1,20 m
-2,50 m
-3,90 m
Net interest expenses
-1,30 m
-1,20 m
-2,50 m
-3,90 m
Depreciation and amortization charges
51,40 m
52,20 m
53,80 m
57,40 m
EBITDA
355,25 m
389,90 m
395,75 m
324,60 m
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer